Traders flee after the company announces that it is merging with a privately held drugmaker.
News & Analysis: Impax Laboratories
These stocks defied a downward-moving market. Find out why.
Analysts upped their price targets following a solid second-quarter report from the drugmaker.
A solid second quarter from the drugmaker.
Shareholders can thank a series of positive developments for the double-digit gains.
A new CEO is sparking optimism that this company can turn a corner to better days.
Lackluster fourth-quarter results sent investors heading for the exits.
Weak third-quarter results and tepid forward guidance cast a shadow on this generic drugmaker.
Cuts to sales and profit guidance could make Impax Labs' shares more expensive relative to earnings than they appear.
Lowered full-year financial guidance is weighing on investors' minds today.